Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Rohto Pharmaceutical Co's 3-1 Month Momentum % is 20.75%.
The industry rank for Rohto Pharmaceutical Co's 3-1 Month Momentum % or its related term are showing as below:
TSE:4527's 3-1 Month Momentum % is ranked better than 89.42% of 2041
companies
in the Consumer Packaged Goods industry
Industry Median: 1.63
vs TSE:4527: 20.75
Rohto Pharmaceutical Co (TSE:4527) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Rohto Pharmaceutical Co 3-1 Month Momentum % Related Terms
TSE:4527 vs PG, CL, EL: 3-1 Month Momentum % Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co 3-1 Month Momentum % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's 3-1 Month Momentum % falls into.
Rohto Pharmaceutical Co (TSE:4527) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co (TSE:4527) has a 3-1 Month Momentum % of 20.75% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Rohto Pharmaceutical Co and its competitors. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #216 out of 2041 companies in the Consumer Packaged Goods industry, placing it in the top 10.6%.
Is Rohto Pharmaceutical Co's 3-1 Month Momentum % too high?
Rohto Pharmaceutical Co's current 3-1 Month Momentum % is 20.75%. The Consumer Packaged Goods industry median 3-1 Month Momentum % is 1.63. Rohto Pharmaceutical Co's value of 20.75% is 1173% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #216 out of 2041 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Rohto Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's 3-1 Month Momentum % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #216 out of 2041 companies for 3-1 Month Momentum %. This places Rohto Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.63. Rohto Pharmaceutical Co's value of 20.75% is 1173% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Consumer Packaged Goods company?
The median 3-1 Month Momentum % among Consumer Packaged Goods companies is 1.63, based on 2,041 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current 3-1 Month Momentum % of 20.75% is 1173% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median 3-1 Month Momentum % is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current 3-1 Month Momentum % is 20.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,111.59, compared to a current price of 円2,784.50 — trading 10.5% below its estimated fair value. The current 3-1 Month Momentum % is 20.75% and 1173% above the Consumer Packaged Goods industry median of 1.63. Rohto Pharmaceutical Co's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current 3-1 Month Momentum % is 20.75% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,784.50 is trading 10.5% below its estimated GF Value™ of 円3,111.59.
GuruFocus considers Rohto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4527:
3-1 Month Momentum %: 20.75%
GF Value™: 円3,111.59 vs. price of 円2,784.50 (10.5% below fair value)
Industry Position: 1173% above the Consumer Packaged Goods median (#216 of 2041)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
90GF Score
Get the complete analysis for TSE:4527
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
